Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The conclusion of the conversation is that CosmeRna may not be an effective treatment for hair loss compared to topical minoxidil 2%. It is suggested to wait for more reviews before purchasing it.

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

RU58841, combined with 5% minoxidil, helped reduce acne and hair loss. Users discussed using RU58841 cream for acne and shared experiences with other treatments like finasteride and dutasteride.

The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.

The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.

The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.

The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.

The conversation is about someone's positive results after one month using RU58841 and minoxidil 5% once a day for hair loss. RU58841 is a topical solution that prevents DHT hormone from binding to hair follicles.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The conversation is about the potential risk of permanent hair loss from PRP (platelet rich plasma) treatments and whether PRF (platelet rich fibrin) carries the same risk. The user is seeking information on this topic.

The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

The conversation is about a person starting treatment with RU58841 for hair loss. They are asked to share progress pictures to show if the treatment is effective.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.